Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start

Hypersensitivity reactions from taxol.

R B Weiss, Ross C. Donehower, Peter H. Wiernik et al. · Journal of Clinical Oncology · 1990 · 1.2K citations

Medicine, Oncology, Pharmacology +9

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety et al. · The Lancet Oncology · 2020 · 442 citations · Full text

Medicine, Oncology, Urology +13

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

Richard Sylvester, Maurizio Brausi, Wim J. Kirkels et al. · European Urology · 2009 · 433 citations · Full text

Medicine, Oncology, Urology +13

EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER

Gary D. Steinberg, Robert Bahnson, Stanley A. Brosman et al. · The Journal of Urology · 2000 · 340 citations

Medicine, Oncology, Urology +6

Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin

Colin P. Dinney, Richard E. Greenberg, Gary D. Steinberg · Urologic Oncology Seminars and Original Investigations · 2012 · 147 citations

Medicine, Oncology, Urology +7